Screening/counseling	Recommendation	Grade; year
Cancer
Cervical	Screen every three years with cervical cytology alone in women 21 to 29 years of age	Grade A; 2018
	Screening women < 21 years is not recommended	Grade D; 2018
Skin: behavioral	Counsel young adults and adolescents with fair skin types about minimizing exposure to ultraviolet radiation	Grade B; 2018
Testicular	Screening is not recommended	Grade D; 2011
Cardiovascular health
Blood pressure (hypertension)	Insufficient evidence to assess the balance of benefits and harms of screening asymptomatic adolescents to prevent cardiovascular disease in childhood or adulthood	Grade I; 2013
	Screen those ≥ 18 years; obtain measurements outside of the clinic setting for diagnostic confirmation before starting treatment	Grade A; 2015
Lipid disorders	Insufficient evidence to assess the balance of benefits and harms of screening ≤ 20 years	Grade I; 2016
General health
Intimate partner violence	Screen women of reproductive age and provide or refer women who screen positive to ongoing support services	Grade B; 2018
Obesity	Screen and offer or refer to comprehensive, intensive behavioral interventions	Grade B; 2017
Prevention of neural tube defects	Recommend that all women who are planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg of folic acid	Grade A; 2017
Scoliosis	Insufficient evidence to assess the balance of benefits and harms of screening in children and adolescents 10 to 18 years of age*	Grade I; 2018
Mental health
Depression	Insufficient evidence to assess the balance of benefits and harms of screening in children ≤ 11 years	Grade I; 2016
	Screen adolescents 12 to 18 years of age and adults, including pregnant and postpartum women; adequate diagnostics, effective treatment, and follow-up should be in place	Grade B; 2016
Suicide risk	Insufficient evidence to assess the balance of benefits and harms of screening adolescents in primary care	Grade I; 2014
Sexually transmitted infections
Behavioral	Provide intensive behavioral counseling for all sexually active adolescents	Grade B; 2014
Chlamydia and gonorrhea	Screen sexually active women ≤ 24 years	Grade B; 2014
	Insufficient evidence to assess the balance of benefits and harms of screening in males	Grade I; 2014
Hepatitis B virus infection	Screen those at high risk of infection (e.g., > 2% hepatitis B virus prevalence in country of origin, HIV infection, injection drug users, household contacts or sex partners of others with hepatitis B virus infection, men who have sex with men, immunocompromised persons, or those in other high-prevalence settings)	Grade B; 2014
	Screen for hepatitis B virus in pregnant women at their first prenatal visit	Grade A; 2019
Herpes simplex virus infection	Routine serologic screening in asymptomatic adolescents is not recommended, including in women who are pregnant	Grade D; 2016
HIV infection	Screen adolescents ≥ 15 years; screen younger adolescents with risk factors†; offer preexposure prophylaxis with effective antiretroviral therapy to those at high risk of HIV acquisition	Grade A; 2019
	Screen pregnant women	Grade A; 2019
Syphilis	Screen adolescents who are at increased risk of infection‡	Grade A; 2016
	Screen pregnant women	Grade A; 2018
Substance abuse
Alcohol	Evidence is insufficient to assess the balance of benefits and harms of screening and brief behavioral counseling interventions for adolescents 12 to 17 years of age	Grade I; 2018
	Screen for unhealthy alcohol use in those ≥ 18 years, including pregnant women, and provide those engaged in risky or hazardous drinking with brief behavioral counseling interventions to reduce unhealthy alcohol use	Grade B; 2018
Tobacco	Provide interventions, including education or brief counseling, to prevent initiation of tobacco use among adolescents	Grade B; 2013
	Ask all individuals ≥ 18 years about tobacco use, advise to stop, and provide behavioral interventions for cessation; if nonpregnant, also offer U.S. Food and Drug Administration–approved pharmacotherapy for cessation	Grade A; 2015
	Evidence is insufficient to assess the balance of benefits and harms of pharmacotherapy intervention for tobacco cessation in pregnant women.	Grade I; 2015
	Evidence is insufficient to recommend electronic nicotine delivery systems for tobacco cessation in adults, including pregnant women.	Grade I; 2015